Clinical data | |
---|---|
Other names | NB-DMT; DMT-BOC; N′-t-BOC-DMT; N′-tert-Butoxycarbonyl-N,N-dimethyltryptamine |
Drug class | Serotonergic psychedelic; Hallucinogen; Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
Chemical and physical data | |
Formula | C17H24N2O2 |
Molar mass | 288.391 g·mol−1 |
3D model (JSmol) | |
| |
|
NBoc-DMT, or NB-DMT, also known as N1-tert-butoxycarbonyl-N,N-dimethyltryptamine, is a serotonergic psychedelic of the tryptamine family.[1][2] It is a novel designer and recreational drug and is a synthetic modification of dimethyltryptamine (DMT) with an N′-tert-butyloxycarbonyl (NBoc) group.[1][2]
NB-DMT is said to be a "prodrug" of DMT that decomposes into DMT when the compound is heated (e.g., with smoking or vaping).[1] It may also be useful as an orally active prodrug of DMT, unlike DMT itself which is inactive when taken orally.[3][4] NB-DMT has been claimed to have about 25% of the potency of DMT by weight.[1]
It was first detected as a designer drug being sold online by February 2024.[1] NB-DMT is a Schedule I controlled substance in Russia.[1] A number of other NBoc designer drugs have also been encountered.[1][5]